FTH.US Faeth Therapeutics, Inc.
- Market cap
- USD 259M
- P/E
- -
- P/B
- 1.71x
- ROE
- -164.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FTH.US undervalued?
Graham numberThe Graham number of Faeth Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Faeth Therapeutics, Inc. fundamental analysis
No fundamental analysis for Faeth Therapeutics, Inc. yet.
Faeth Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes …
Full company profileFaeth Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Faeth Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -44.0K | -73.0K | -209K | -685K | -1.81M | -571K | -551K | - | - |
| Operating Income | -12.7M | -12.4M | -19.5M | -37.5M | -49.1M | -37.1M | -31.7M | -22.3M | -281M |
| EBITDA | -12.7M | -14.4M | -18.2M | -35.4M | -47.0M | -35.6M | -28.7M | -20.9M | -278M |
| Net Income | -13.0M | -16.7M | -20.1M | -36.8M | -48.6M | -34.1M | -30.2M | -21.1M | -276M |
| EPS | -8.89 | -11 | -13 | -27 | -32 | -24 | -24 | -17 | -11 |
| Balance Sheet | |||||||||
| Total Assets | 1.85M | 1.22M | 21.4M | 153M | 118M | 74.4M | 45.4M | 22.9M | 179M |
| Total Liabilities | 55.3M | 69.9M | 5.54M | 6.71M | 15.0M | 9.48M | 6.98M | 4.31M | 11.1M |
| Shareholders' Equity | -53.5M | -68.7M | 15.9M | 147M | 103M | 64.9M | 38.4M | 18.6M | 168M |
| Cash & Short-term Investments | 653K | 251K | 16.6M | 148M | 107M | 65.8M | 41.3M | 21.2M | 175M |
| Total Debt | 4.75M | 16.1M | 685K | 2.35M | 8.03M | 6.21M | 3.85M | 1.51M | 145K |
| Cash Flow | |||||||||
| Operating Cash Flow | -10.3M | -8.57M | -17.7M | -30.3M | -39.0M | -32.0M | -24.7M | -20.5M | -52.5M |
| Capital Expenditure | 31.0K | 53.0K | 1.21M | 2.03M | 321K | 180K | 146K | 16.0K | 20.0K |
| Free Cash Flow | -10.3M | -8.62M | -18.9M | -32.3M | -39.3M | -32.2M | -24.8M | -20.5M | -52.6M |
| Ratios | |||||||||
| ROE | - | - | -126.5% | -25.1% | -47.0% | -52.5% | -78.6% | -113.4% | -164.1% |
| ROA | -704.8% | -1,375.5% | -93.8% | -24.0% | -41.0% | -45.9% | -66.5% | -92.1% | -154.0% |
| Debt to Equity | - | - | 0.04x | 0.02x | 0.08x | 0.10x | 0.10x | 0.08x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Faeth Therapeutics, Inc. dividends
Faeth Therapeutics, Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 1:20 on Jun 17, 2025.
Who owns Faeth Therapeutics, Inc.
- Insiders 4.95%
- Institutions 81.11%
- Public & others 13.95%
- Shares outstanding 25.8M
- Free float 18.5M
Top funds holding FTH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Polar Capital Biotech S Inc | 1.22M | 4.72% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 707K | 2.74% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 337K | 1.30% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 230K | 0.89% | +2.67% | Oct 2026 |
| Franklin Biotechnology Discovery A | 181K | 0.70% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 103K | 0.40% | +0.22% | Oct 2026 |
| Fidelity Extended Market Index | 89.8K | 0.35% | +1,880.14% | Sep 2026 |
| iShares Micro-Cap ETF | 74.5K | 0.29% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 38.7K | 0.15% | +2,630.51% | Sep 2026 |
| Fidelity Series Total Market Index | 31.2K | 0.12% | +2,389.47% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 29.4K | 0.11% | +0.03% | Oct 2026 |
| BlueBox Precision Medicine S USD Acc | 22.0K | 0.09% | 0.00% | Jul 2026 |
| Schwab US Broad Market ETF™ | 12.4K | 0.05% | 0.00% | Oct 2026 |
| Vanguard Balanced Index Inv | 12.0K | 0.05% | 0.00% | Sep 2026 |
| Schwab Total Stock Market Index | 12.0K | 0.05% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 10.8K | 0.04% | 0.00% | Sep 2026 |
| Direxion Daily S&P Biotech Bull 3X ETF | 9.43K | 0.04% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite ETF | 9.18K | 0.04% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 7.51K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 5.55K | 0.02% | -65.08% | Aug 2026 |
Top institutions holding FTH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2.02M | 7.82% | +5,747.07% | Jun 2026 |
| venBio Select Advisor LLC | 1.44M | 5.59% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 1.29M | 4.98% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 1.04M | 4.03% | +6,331.34% | Jun 2026 |
| Cormorant Asset Management, LLC | 1.03M | 3.98% | +235.78% | Jun 2026 |
| Vivo Capital, LLC | 722K | 2.79% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 722K | 2.79% | 0.00% | Jun 2026 |
| Fairmount Funds Management LLC | 722K | 2.79% | 0.00% | Jun 2026 |
| Logos Global Management LP | 722K | 2.79% | +2,306.73% | Jun 2026 |
| Caligan Partners LP | 629K | 2.44% | +399.57% | Jun 2026 |
| B Group, Inc | 610K | 2.36% | 0.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 515K | 1.99% | +312.27% | Jun 2026 |
| Franklin Templeton Inc | 495K | 1.91% | +270.41% | Jun 2026 |
| ADAR1 Capital Management LLC | 361K | 1.40% | 0.00% | Jun 2026 |
| Octagon Capital Advisors LP | 361K | 1.40% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 207K | 0.80% | +214.18% | Jun 2026 |
| Boxer Capital Management, LLC | 181K | 0.70% | 0.00% | Jun 2026 |
| Patient Square Capital LP | 175K | 0.68% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 144K | 0.56% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 144K | 0.56% | 0.00% | Jun 2026 |
Faeth Therapeutics, Inc. company profile
- Company name
- Faeth Therapeutics, Inc.
- Ticker
- FTH.US
- Exchange
- USA Stocks
- Listed since
- Feb 4, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 1405 Research Boulevard, Rockville, MD, United States, 20850
- Phone
- 240 243 8000
- Website
- faeththerapeutics.com
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
Faeth Therapeutics, Inc. management
10- Mr. Josiah Craver CPASenior VP of Finance, Principal Financial Officer & Principal Accounting Officer
- Mr. Christopher W. Gerry J.D.General Counsel & Secretary · born 1980
- Mr. Anand Parikh Esq., J.D.CEO, President & Chair · born 1986
- Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.Scientific Co-Founder · born 1971
- Dr. Lewis clayton Cantley Ph.D.Scientific Co-Founder · born 1949
- Dr. Scott W. Lowe Ph.D.Scientific Co-Founder
- Dr. Gregory J. Hannon Ph.D.Scientific Co-Founder
- Dr. Karen H. Vousden Ph.D.Scientific Co-Founder & Director · born 1958
- Mr. Oliver Maddocks Ph.D.Co-Founder & Chief Scientific Officer
- Dr. Benjamin Hopkins Ph.D.Scientific Co-Founder